卵巢组织卵母细胞体外成熟用于生育力保存后的活产
这项回顾性队列研究纳入2012年1月至2019年5月接受单侧卵巢切除行卵巢组织冷冻保存的77例患者,将卵巢组织处理中获得的卵丘-卵母细胞复合体体外成熟28-42小时,成熟卵母细胞行玻璃化或受精后胚胎玻璃化。12例患者有妊娠意愿,其中7例解冻卵母细胞或胚胎,最终获得3例健康活产,每例患者活产率为43%。
要点
- 卵巢组织卵母细胞体外成熟(OTO-IVM)联合卵巢组织冷冻保存(OTC)是紧急生育力保存的有价值辅助技术。
- 共采集1220个卵丘-卵母细胞复合体,平均卵母细胞成熟率为39%±23%(SD)。
- 在12例有妊娠意愿的患者中,7例使用OTO-IVM材料,获得3例健康活产,每例患者活产率为43%。
核心结论
- OTO-IVM联合OTC是生育力保存的有价值辅助技术,本研究首次报告了该辅助技术联合卵母细胞玻璃化后的活产。
研究设计与样本
- 回顾性队列研究,2012年1月至2019年5月在大学医院附属生育诊所开展。
- 纳入77例接受单侧卵巢切除行OTC的患者,卵巢组织处理中获取的COCs体外成熟28-42小时,成熟卵母细胞行玻璃化或受精后胚胎玻璃化。
主要发现
- 共采集1220个COCs,平均卵母细胞成熟率为39%±23%(SD)。
- 64例患者行卵母细胞玻璃化,每例患者6.7±6.3个卵母细胞。
- 13例患者行IVM后成熟卵母细胞ICSI,每例患者2.0±2.0个胚胎玻璃化。
- 12例患者有妊娠意愿,其中7例解冻OTO-IVM材料;2例患者解冻OTO-IVM卵母细胞,存活率分别为86%和60%。
- 5例患者平均2.0±0.8(SD)个胚胎玻璃化,共解冻7个胚胎:1个未存活,2个遗传学检测不适合移植,4个移植给3例不同患者,获得2例健康婴儿;每例患者活产率为43%。
局限性
- 回顾性研究设计。
- 样本量有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Can oocytes extracted from excised ovarian tissue and matured in vitro be a useful adjunct for urgent fertility preservation (FP)? SUMMARY ANSWER: Ovarian tissue oocyte in-vitro maturation (OTO-IVM) in combination with ovarian tissue cryopreservation (OTC) is a valuable adjunct technique for FP. WHAT IS KNOWN ALREADY: Despite the impressive progress in the field, options for FP for cancer patients are still limited and, depending on the technique, clinical outcome data are still scarce. STUDY DESIGN, SIZE, DURATION: This was a retrospective cohort study conducted at a university hospital-affiliated fertility clinic between January 2012 and May 2019. PARTICIPANTS/MATERIALS, SETTING, METHODS: The study included 77 patients who underwent unilateral oophorectomy for OTC. Cumulus-oocyte complexes (COCs) obtained during ovarian tissue processing were matured in vitro for 28-42 h. Oocytes reaching metaphase II stage were vitrified or inseminated for embryo vitrification. MAIN RESULTS AND THE ROLE OF CHANCE: Overall, 1220 COCs were collected. The mean oocyte maturation rate was 39% ± 23% (SD). There were 64 patients who had vitrification of oocytes (6.7 ± 6.3 oocytes per patient). There were 13 patients who had ICSI of mature oocytes after IVM, with 2.0 ± 2.0 embryos vitrified per patient. Twelve patients have returned to the clinic with a desire for pregnancy. For seven of these, OTO-IVM material was thawed. Two patients had OTO-IVM oocytes warmed, with survival rates of 86% and 60%. After ICSI, six oocytes were fertilised in total, generating three good quality embryos for transfer, leading to a healthy live birth for one patient. In five patients, for whom a mean of 2.0 ± 0.8 (SD) embryos had been vitrified, seven embryos were warmed in total: one embryo did not survive the warming process; two tested genetically unsuitable for transfer; and four were transferred in separate cycles to three different patients, resulting in two healthy babies. In this small series, the live birth rate per patient after OTO-IVM, ICSI and embryo transfer was 43%. LIMITATIONS, REASONS FOR CAUTION: The retrospective study design and the limited sample size should be considered when interpreting results. WIDER IMPLICATIONS OF THE FINDINGS: The results of the study illustrate the added value of OTO-IVM in combination with OTC. We report the first live birth following the use of this appended technique combined with oocyte vitrification. STUDY FUNDING/COMPETING INTEREST(S): No external funding was used for this study. M.D.V. reports honoraria for lectures in the last 2 years from MSD and Ferring, outside the submitted work, as well as grant support from MSD. The other authors have nothing to declare. TRIAL REGISTRATION NUMBER: N/A.
引用
- Segers I, Bardhi E, Mateizel I, et al. Live births following fertility preservation using in-vitro maturation of ovarian tissue oocytes. Hum Reprod. 2020. PMID: 32829388. doi:10.1093/humrep/deaa175
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。